Cancer, diabetes and eczema star in 2017 top-launch list
Launch prognostications are getting more attention than ever as they come out with “Drugs to Watch” list, and the highlights of different drugs shows what might work this year. By 2021, some of the drugs in the list are expected to bring in $16 billion, shared among Big Pharma and a few top biotechs. Some of the usual suspects are Roche’s Ocrevus; Sanofi and Regeneron’s Dupixent; AstraZeneca’s durvalumab; Novo Nordisk’s semaglutide; Tesaro’s niraparib, just approved as Zejula; Novartis’ LEE011, a.k.a. ribociclib, approved last month under the Kisqali brand name; and Kite Pharma’s KTE-C19, which could be the first...
